Association Between Tumor Expression of VEGFA, VEGFR1 (FLT1), VEGFR2 (KDR), and Clinical Outcomes in Neuroendocrine Tumors Abstract #823

Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Aim(s): We investigated the prognostic significance of expression of VEGF pathway components in NET patients generally, and in a subgroup of patients treated with bevacizumab.
Materials and methods: We evaluated immunohistochemical expression of VEGFA, VEGFR1, and VEGFR2 in a cohort of archival NETs and evaluated associations with overall survival (OS) and progression-free survival (PFS) after adjusting for other clinical prognostic variables.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result